文献速递白血病

Pracinostat联合阿扎胞苷治疗新诊断老年急性髓系白血病患者的2期研究结果

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.
PubMed 文献 · Blood Adv · 2019-01-01

这项单组、多中心2期研究评估了Pracinostat联合阿扎胞苷在≥65岁、不适合标准诱导化疗的新诊断急性髓系白血病患者中的安全性和疗效。50例患者中26例(52%)达到主要终点,中位总生存期19.1个月,中位无进展生存期12.6个月,1年总生存率62%。

要点

  • Pracinostat 60 mg/d每周3天连续3周联合阿扎胞苷75 mg/m2每日7天,28天为一周期。
  • 50例患者中26例(52%)达到主要终点:完全缓解42%、伴计数恢复不全的完全缓解4%、形态学无白血病状态6%。
  • 43例(86%)发生至少1次3级及以上治疗中出现的不良事件,最常见为感染(52%)、血小板减少(46%)和发热性中性粒细胞减少(44%)。

核心结论

  • Pracinostat联合阿扎胞苷在不适合强化治疗的老年急性髓系白血病患者一线治疗中耐受性良好且具有活性。
  • 一项更大规模的对照试验正在进行中。

研究设计与样本

  • 单组、多中心2期研究,纳入至少65岁、新诊断且不适合标准诱导化疗的急性髓系白血病患者。
  • 共入组50例患者(33例原发、12例继发、5例治疗相关急性髓系白血病)。
  • 患者接受Pracinostat 60 mg/d、每周3天、连续3周,联合阿扎胞苷75 mg/m2每日1次、连续7天,28天为一周期。
  • 主要终点为完全缓解、伴计数恢复不全的完全缓解和形态学无白血病状态率;次要终点包括安全性、无进展生存期和总生存期。

主要发现

  • 26例患者(52%)达到主要终点:完全缓解42%、伴计数恢复不全的完全缓解4%、形态学无白血病状态6%。
  • 中位总生存期为19.1个月(95%CI,10-26.5个月),中位无进展生存期为12.6个月(95%CI,10-17.7个月),1年总生存率为62%。
  • 43例患者(86%)发生至少1次3级及以上治疗中出现的不良事件,最常见为感染(52%)、血小板减少(46%)和发热性中性粒细胞减少(44%)。
  • 30天和60天全因死亡率分别为2%和10%。
  • DNA测序显示基线存在体细胞突变,且清除率与治疗反应相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pracinostat, a potent oral pan-histone deacetylase inhibitor with modest single-agent activity in acute myeloid leukemia (AML), has shown synergistic antitumor activity when combined with azacitidine. This single-group, multicenter phase 2 study assessed the safety and efficacy of pracinostat combined with azacitidine in patients who were at least 65 years old with newly diagnosed AML and who were ineligible for standard induction chemotherapy. Patients received pracinostat 60 mg/d, 3 d/wk, for 3 consecutive weeks, plus azacitidine 75 mg/m2 daily for 7 days in a 28-day cycle. Primary endpoints were complete remission (CR), CR with incomplete count recovery (CRi), and morphologic leukemia-free state (MLFS) rates of the combination. Secondary endpoints included safety, progression-free survival (PFS), and overall survival (OS) of the regimen. Fifty patients (33 de novo, 12 secondary, and 5 therapy-related AML) were enrolled. Twenty-six patients (52%) achieved the primary endpoint of CR (42%), CRi (4%), and MLFS (6%). Median OS and PFS were 19.1 months (95% confidence interval [CI], 10-26.5 months) and 12.6 months (95% CI, 10-17.7 months), respectively, with a 1-year OS rate of 62%. Forty-three patients (86%) experienced at least 1 grade 3 or worse treatment-emergent adverse event with the combination, with infections (52%), thrombocytopenia (46%), and febrile neutropenia (44%) reported as the most common toxicities. The 30- and 60-day all-cause mortality rates were 2% and 10%, respectively. DNA sequencing revealed somatic mutations at baseline, and clearance rates correlated with response to treatment. Pracinostat plus azacitidine is a well-tolerated and active regimen in the frontline treatment of older patients with AML unfit for intensive therapy. A larger controlled trial is ongoing. This trial was registered at www.clinicaltrials.gov as #NCT01912274.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Garcia-Manero G, Abaza Y, Takahashi K, et al. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Adv. 2019. PMID: 30760466. doi:10.1182/bloodadvances.2018027409

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。